Literature DB >> 469523

Effects of intranigral administration of dopamine agonists and antagonists and baclofen on concentrations of dopac and dopamine in the striatum and substantia nigra of the rat.

S M Wuerthele, N M Friedle, K E Moore.   

Abstract

Systemic administration of haloperidol to rats failed to alter the concentration of dopamine but increased the concentration of 3,4-dihydroxy-phenylacetic acid (DOPAC), the major metabolite of dopamine, in both the striatum and substantia nigra. These haloperidol-induced changes in DOPAC were prevented by an intranigral microinjection of baclofen, a drug which reduces nigrostriatal dopaminergic neuronal activity. It has been proposed that nigrostriatal neurons are regulated, in part, by the activation of autoreceptors in substantia nigra. However, intranigral microinjections of high concentrations of several dopaminergic antagonists failed to mimic the biochemical effects resulting from systemic administration of these drugs; instead, they slightly increased the concentrations of both dopamine and DOPAC in the striatum and decreased dopamine in substantia nigra. Intranigral microinjections of the dopamine agonist, apomorphine, failed to alter the concentration of DOPAC in the striatum, but reduced both dopamine and DOPAC in the nigra. If DOPAC concentrations reflect nigrostriatal dopaminergic neuronal activity, the present results suggest that dopaminergic agonists and antagonists acting in substantia nigra do not exert a major influence on the activity of these neurons.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 469523     DOI: 10.1007/bf01250087

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  27 in total

1.  Dopamine in dendrites of substantia nigra neurons: suggestions for a role in dendritic terminals.

Authors:  A Björklund; O Lindvall
Journal:  Brain Res       Date:  1975-01-17       Impact factor: 3.252

2.  Differential effect of psychotropic drugs on dihydroxyphenylacetic acid (DOPAC) in the rat substantia nigra and caudate nucleus.

Authors:  F Fadda; A Argiolas; E Stefanini; G L Gessa
Journal:  Life Sci       Date:  1977-08-01       Impact factor: 5.037

3.  Apomorphine-induced inhibition of striatal dopamine release: role of dopaminergic receptors in substantia nigra.

Authors:  A Maggi; F Bruno; F Cattabeni; A Groppetti; M Parenti; G Racagni
Journal:  Brain Res       Date:  1978-04-21       Impact factor: 3.252

4.  Transmitter metabolism in substantia nigra after inhibition of dopaminergic neurones by butyrolactone.

Authors:  F Hefti; R Lienhart; W Lichtensteiger
Journal:  Nature       Date:  1976-09-23       Impact factor: 49.962

5.  Nigral and striatal dopamine release under sensory stimuli.

Authors:  A Nieoullon; A Cheramy; J Glowinski
Journal:  Nature       Date:  1977-09-22       Impact factor: 49.962

6.  Effects of baclofen on dopamine metabolism and interaction with neuroleptic effects.

Authors:  P C Waldmeier; L Maitre
Journal:  Eur J Pharmacol       Date:  1978-01-15       Impact factor: 4.432

Review 7.  Effect of enkephalins on catecholamine metabolism in rat CNS.

Authors:  S Algeri; N Brunello; G Calderini; A Consolazione
Journal:  Adv Biochem Psychopharmacol       Date:  1978

8.  Central dopaminergic neurons: effects of alterations in impulse flow on the accumulation of dihydroxyphenylacetic acid.

Authors:  R H Roth; L C Murrin; J R Walters
Journal:  Eur J Pharmacol       Date:  1976-03       Impact factor: 4.432

9.  Inhibition by neuroleptics of uptake of 3H-GABA into rat brain synaptosomes.

Authors:  B Fjalland
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1978-01

10.  Increase in mouse brain dopamine content by baclofen: effects of apomorphine and neuroleptics.

Authors:  G Gianutsos; K E Moore
Journal:  Psychopharmacology (Berl)       Date:  1977-05-09       Impact factor: 4.530

View more
  1 in total

1.  Behavioral differences induced by muscimol selectively injected into pars compacta and pars reticulata of Substantia nigra.

Authors:  J Arnt; J Scheel-Krüger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-12       Impact factor: 3.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.